DWK-1339 – 5 mg

Brand:
Cayman
CAS:
1018946-38-7
Storage:
-20
UN-No:
Non-Hazardous - /

DWK-1339 is an inhibitor of amyloid-β (Aβ) aggregation.{35159} It inhibits aggregation of monomeric Aβ (1-42) (Aβ42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 µM. DWK-1339 (10 µM) reduces Aβ42-induced toxicity in HT-22 cells. In vivo, DWK-1339 (10 mg/kg) increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer’s disease. It also decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer’s disease.  

 

Available on backorder

SKU: 27642 - 5 mg Category:

Description

An inhibitor of amyloid-β aggregation; inhibits aggregation of monomeric Aβ42 and induces disaggregation of Aβ42 fibrils in vitro from 3.1-50 µM; reduces Aβ42-induced toxicity in HT22 cells at 10 µM; increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer’s disease at 10 mg/kg; decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer’s disease


Formal name: 2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)-benzofuran

Synonyms:  MDR-1339,

Molecular weight: 326.4

CAS: 1018946-38-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease